Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Amalgamated Bank

Amalgamated Bank raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 52.4% during the second quarter, Holdings Channel reports. The institutional investor owned 7,152 shares of the company’s stock after buying an additional 2,459 shares during the period. Amalgamated Bank’s holdings in Recursion Pharmaceuticals were worth $54,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of RXRX. Dimensional Fund Advisors LP boosted its holdings in shares of Recursion Pharmaceuticals by 152.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,137,110 shares of the company’s stock valued at $21,079,000 after buying an additional 1,291,946 shares in the last quarter. UBS Group AG raised its holdings in Recursion Pharmaceuticals by 101.9% during the fourth quarter. UBS Group AG now owns 691,911 shares of the company’s stock worth $6,822,000 after purchasing an additional 349,232 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at about $1,348,000. Mubadala Investment Co PJSC purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $128,041,000. Finally, Vanguard Group Inc. increased its position in Recursion Pharmaceuticals by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock worth $154,459,000 after purchasing an additional 158,376 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Down 6.4 %

Shares of NASDAQ:RXRX opened at $6.17 on Wednesday. The stock has a 50-day simple moving average of $6.95 and a 200-day simple moving average of $8.12. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same period in the previous year, the company earned ($0.38) earnings per share. The business’s quarterly revenue was up 30.9% on a year-over-year basis. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on RXRX shares. Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.40.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total value of $83,792.04. Following the sale, the director now directly owns 7,167,110 shares in the company, valued at approximately $52,463,245.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total transaction of $83,792.04. Following the sale, the director now owns 7,167,110 shares of the company’s stock, valued at $52,463,245.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $8.13, for a total value of $48,780.00. Following the completion of the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,353,265.41. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 231,682 shares of company stock valued at $1,632,044. Insiders own 15.75% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.